News

Cytovale's IntelliSep®: A Leader in Sepsis Testing Innovation

Cytovale's IntelliSep®: A Leader in Sepsis Testing Innovation

Cytovale's IntelliSep® Recognized by Modern Healthcare

Cytovale's IntelliSep® has earned recognition as one of Modern Healthcare's Best in Business for the second consecutive year, showcasing its innovative approach to sepsis care. This noteworthy achievement highlights the profound impact IntelliSep has had in assisting healthcare providers in saving lives in emergency departments.

What Makes IntelliSep Stand Out?

IntelliSep is a state-of-the-art rapid sepsis test designed for emergency department (ED) clinicians. It provides objective measurements of immune dysregulation, which is a significant contributor to the onset of sepsis. By delivering results in approximately eight minutes, it allows for swift risk assessments during triage, accelerating timely care for high-risk patients and minimizing unnecessary treatments for those at lower risk.

Impact on Patient Outcomes

Since its launch, IntelliSep has been utilized in the evaluation of over 70,000 patients across various healthcare systems. Recent studies have demonstrated substantial improvements in clinical outcomes, with hospitals using the test achieving a 39% reduction in sepsis mortality rates. Additionally, they have managed to shorten the average hospital stay for patients diagnosed with sepsis by nearly a full day. Notably, there has been an impressive 80% decline in Code Sepsis alerts associated with the usage of IntelliSep, facilitating a more efficient resource allocation in the ED.

Insights from Medical Professionals

Dr. Christopher Thomas, the Vice President and Chief Quality Officer at a leading health system, noted that in the ED, timely detection of life-threatening conditions like sepsis is crucial. He emphasized that IntelliSep plays a pivotal role in enabling ED teams to swiftly and accurately detect or rule out sepsis, thereby improving patient management during critical moments.

Recognition and Industry Impact

The Best in Business program by Modern Healthcare identifies organizations that are pushing the boundaries of innovation, efficiency, and excellence within the healthcare sector. Recipients are recognized for their ability to make a tangible difference in care delivery and operational effectiveness.

As stated by Dan Peres, President of Modern Healthcare, these organizations exemplify the creativity and progress necessary to enhance healthcare delivery. The impact of their innovation is setting new standards for what is possible in patient care and operational efficiency.

Statements from Cytovale Leadership

Ajay Shah, Co-founder and CEO of Cytovale, remarked that receiving this award signifies a broader acknowledgment of the need for more precise diagnostic approaches for sepsis. IntelliSep was designed to offer rapid and accurate detection of immune dysregulation in the ED, thus facilitating consistent and systematic evaluations of sepsis. With wider adoption across numerous health systems, this recognition underscores the necessity of innovative solutions in enhancing patient care.

IntelliSep®: A Game Changer in Diagnostics

The IntelliSep® test is distinguished as the only FDA-cleared rapid sepsis diagnostic for use in Emergency Departments. By utilizing advanced microfluidics and artificial intelligence technology, it provides clinicians with a sensitive and objective detection tool for sepsis. The test evaluates immune system responses to infection and generates a risk score for sepsis within minutes from a standard blood draw, thereby fostering rapid decision-making in patient care.

About Cytovale

Cytovale is dedicated to enhancing patient care through the development of pioneering detection technologies that focus on immune activation. The company aims to shorten the time from triage to life-saving treatments by providing rapid diagnostics, such as IntelliSep®, for assessing sepsis risk with minimal delay. Based in San Francisco, Cytovale has garnered significant backing from venture capital firms.

Frequently Asked Questions

What is the purpose of IntelliSep®?

IntelliSep® is designed to quickly diagnose sepsis by assessing immune dysregulation, enabling faster treatment options in emergency departments.

How has IntelliSep® improved patient care?

It has significantly reduced sepsis mortality rates, shortened hospital stays, and utilized resources more efficiently by decreasing unnecessary procedures.

Who oversees the Best in Business program?

The program is managed by Modern Healthcare, recognizing organizations that excel in innovation and operational efficiency in healthcare.

What is sepsis and why is it critical to diagnose early?

Sepsis is a life-threatening condition caused by the body’s response to infection. Early diagnosis is crucial to enhance treatment outcomes and reduce mortality rates.

Where can I find more information about Cytovale?

For more details on Cytovale and IntelliSep®, visit their official website to learn about their innovative diagnostic solutions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 185

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
Gentex Shares Tumble Amid Legal Investigation Concerns

Updated Category News Views 10

Gentex's Financial Outlook Takes a Hit Well, here we are again, catching another corporate hiccup. Gentex Corporation, or as ticker hounds know it, NASDAQ:GNTX, just pulled the rug out from its investors by chopping the top off its 2026 revenue guidance. Dropping to a floor it once considered a ceiling, $2.65 billion is now the most optimistic number they're pitching. No...

Continue Reading
Millrose Faces Securities Fraud Suit Amidst Decline

Updated Category News Views 148

Dark Clouds Over Millrose Properties Holy smokes, folks, if Millrose Properties thought it could skirt under the radar, they were dead wrong. The curtain's been peeled back, and what do we see? A mess of securities fraud allegations and financial hiccups that’s driving its shareholders mad. October wasn’t too friendly—Hunterbrook Media dropped a bombshell revealing...

Continue Reading
Tony Perkins' Church Tour amid Controversial Vote

Updated Category News Views 89

Lining the pews in Missouri and Kansas, folks are about to get a powerful dose of Tony Perkins this weekend. The Family Research Council President is driving straight into the heart of both spiritual and political fervor at a couple of church stops on Sunday, October 25—right on the doorstep of a crucial vote in Missouri. Taking the Stage in a Time of Tension Now,...

Continue Reading
Howard Hughes Joins S&P SmallCap 600, Arcosa Out

Updated Category News Views 45

Shakeup in the S&P SmallCap 600 It’s one of those days where something shifts in the market landscape—Howard Hughes Holdings Inc. (NYSE: HHH) is swaggering into the S&P SmallCap 600. Kicking off on October 28, it's got quite the entrance lined up. On the other end, Arcosa Inc. (NYSE: ACA) is making a hasty exit after getting scooped up by CRH plc (NYSE: CRH). For...

Continue Reading
Think Together Marks 20 Years of ASES Impact in CA

Updated Category News Views 77

Hands-on Learning: California's Bright Future Starts Here Who's ever thought a schoolyard's the same after three? Let me tell you, in California, it's staying alive and kicking, thanks to Think Together's whirlwind of celebrations for the After School Education and Safety (ASES) program. We're talking 450 schoolyard shindigs highlighting not just how far expanded learning...

Continue Reading
Civista Welcomes Healthcare Leader to Boost Growth

Updated Category News Views 145

Expanding the Boardroom with Healthcare Expertise In an unexpected twist for Civista Bancshares (NASDAQ: CIVB), the financial holding company is roping in some healthcare brass to its board. Jeremy Normington-Slay just snagged a seat at Civista's table, and he's bringing his tough-sledding healthcare leadership chops straight from Firelands Health. A $4.3 billion outfit...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 58

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
Quest Diagnostics Faces Class Action After Data Breach

Updated Category News Views 4

Data Breach Rocks Quest Diagnostics October 2026 caught Quest Diagnostics in a bind they wish they could escape—a classic tech breach with personal info hanging out to dry. When a cyber ghost slipped into Quest's Quanum Lab Services Manager, it wasn't to deliver flowers. Nope, this unauthorized access was no friendly visit, forcing Quest to scream foul and play serious...

Continue Reading
Duolingo Faces Class Action: Deadline Looms for Plaintiffs

Updated Category News Views 115

Shaking up the education sector like a hot potato, investors have been thrown for a loop with Duolingo’s latest legal debacle. News broke that Kahn Swick & Foti, LLC, with significant backing from their heavyweight partner and former Louisiana Attorney General Charles C. Foti Jr., is spearheading a class action lawsuit against Duolingo, Inc. (NasdaqGS: DUOL). It’s one...

Continue Reading

Top 5 Most Recently Viewed Articles

IO Biotech Secures Substantial Debt Financing to Advance Cancer Vaccines

Updated Category News Views 218

Introduction to IO Biotech's Recent Financing IO Biotech, a prominent clinical-stage biopharmaceutical firm, has recently taken a significant step towards enhancing its financial capacity. This move comes in the form of a loan of up to €57.5 million from the European Investment Bank (EIB), an institution dedicated to boosting sustainable ventures within the European...

Continue Reading
Gold Prices Surge: Mining Companies Expand Potential with Rising Markets

Updated Category News Views 247

Gold Prices Remain Elevated As gold prices stabilize above $4,100 per ounce, the mining industry is experiencing unprecedented profit margins. Recent trends in the market indicate significant growth, with a notable increase in activity among exploration and development companies. Buyers and investors alike are capitalizing on the bullish climate within the precious metals...

Continue Reading
Esperion's Strong Q2 2025 Results Highlight Growth Strategy

Updated Category News Views 148

Esperion Celebrates Impressive Growth in Q2 2025 Esperion (NASDAQ: ESPR) recently reported significant financial results for the second quarter ended June 30, 2025, demonstrating a robust year-over-year performance and a commitment to advancing its cardiovascular therapies. Total revenue reached $82.4 million, reflecting a 12% growth as compared to the same period in...

Continue Reading
Understanding the Shift in AMD Options Trading Dynamics

Updated Category News Views 196

What’s Happening with AMD Options Trading? Advanced Micro Devices (NASDAQ: AMD) continues to draw significant attention from high-value investors who appear to be optimistic about the company's future. Recent trades suggest that these investors are adopting a bullish stance, a clear signal for retail traders to take notice. Interpreting Unusual Options Activity...

Continue Reading
Growing Demand for Ternary Cathode NCM Materials in EVs

Updated Category News Views 105

Understanding the Ternary Cathode NCM Material Market The global Ternary Cathode NCM Material market is experiencing significant growth due to a surge in demand for electric vehicle (EV) batteries. Initially valued at approximately USD 9.156 billion, this market is projected to reach an impressive USD 28.65 billion by 2031, reflecting a robust compound annual growth rate...

Continue Reading